RIVA-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.
Brand(s)
Last updated
Summary
Product
RIVA-FLUOXETINE 10mg
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Distribution
National
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
LABORATOIRE RIVA INC. |
RIVA-FLUOXETINE |
DIN 02305461 |
Capsule |
FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 10mg |
D1196, D1513, D1831, D2026 & D2610 |
Issue
The affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Laboratoire Riva Inc. 660 Boul. Industriel, Blainville, QC, J7C 3V4
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
National
Recall class
Type I
Identification number
RA-77354
Get notified
Receive notifications for new and updated recalls and alerts by category.